Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast

trastuzumab  Trastuzumab ซึ่งสามารถลดอัตราการเสียชีวิตได้ถึง 24%และถ้าหากใช้ ยามุ่งเป้าชนิดต้าน HER2 – Trastuzumab กับ Pertuzumab ร่วมกับยาเคมีบำบัด จะสามารถลดอัตราการ A study of more than 4000 patients, published in 2014, showed that adding trastuzumab to chemotherapy led to a 37% relative improvement in

Cardiotoxicity Trastuzumab is a monoclonal antibody tyrosine kinase inhibitor that targets the HER2 receptor often over overexpressed or overactive in breast trastuzumab Early breast cancer Herceptin is indicated for the treatment of patients with HER2-positive early breast cancer: following surgery

Trastuzumab is a biologic therapy indicated for the treatment of human epidermal growth factor receptor 2 -positive breast cancer and Trastuzumab prolongs survival in metastatic breast cancer patients whose tumors over express HER2 It is effective when given as a single agent or in